Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Capital Expenditure (capex)?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Capital Expenditure (capex) is 
-$959.3M (1Y +19.9% )

AMGN Stock Price & Capital Expenditure (capex)

Capital Expenditure (capex) for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Capital Expenditure (capex)

chevron_right 2021 -$173.0M +4.3x
( +5.2% / year avg)
chevron_left 1989 -$32.9M
vertical_align_top Peak -$32.9M +0.98x
vertical_align_bottom Bottom -$1.5B
arrow_drop_up # Up Years 18 18 of 33
years up.
arrow_drop_down # Down Years 15
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or +263x faster than it's capital expenditure (capex) over the same period.
  • If AMGN grows it's stock at the same rate as it's capital expenditure (capex) (+5.2%/year) , it's stock price will grow +166% and hit $409.65 over the next 10 years.
  • AMGN's stock price has gone up 13 of the 18 years (+72%) it's capital expenditure (capex) were also up.
  • AMGN Historical Capital Expenditure (capex) Table

    Year Capital Expenditure (capex) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 -173,000,000.0 -81.3% $246.75 0.0%
    4/1/2020 -923,000,000.0 40.9% $246.75 7.3%
    4/1/2019 -655,000,000.0 -1.7% $229.96 16.1%
    4/1/2018 -666,000,000.0 -20.4% $198.0 22.0%
    4/1/2017 -837,000,000.0 16.9% $162.25 25.3%
    4/1/2016 -716,000,000.0 -8.4% $129.45 -8.2%
    4/1/2015 -782,000,000.0 -9.7% $141.03 -0.6%
    4/1/2014 -866,000,000.0 25.1% $141.87 47.7%
    4/1/2013 -692,000,000.0 -2.9% $96.04 30.8%
    4/1/2012 -713,000,000.0 35.8% $73.4 56.3%
    4/1/2011 -525,000,000.0 -3.1% $46.96 11.0%
    4/1/2010 -542,000,000.0 -3.9% $42.29 -6.5%
    4/1/2009 -564,000,000.0 -22.5% $45.23 1.5%
    4/1/2008 -728,000,000.0 -48.6% $44.58 0.5%
    4/1/2007 -1,417,000,000.0 28.9% $44.34 -22.2%
    4/1/2006 -1,099,000,000.0 22.4% $57.02 -12.2%
    4/1/2005 -898,000,000.0 -38.7% $64.96 34.8%
    4/1/2004 -1,465,300,000.0 23.3% $48.19 4.2%
    4/1/2003 -1,188,100,000.0 122.8% $46.25 22.1%
    4/1/2002 -533,200,000.0 23.9% $37.88 -28.9%
    4/1/2001 -430,200,000.0 35.3% $53.32 4.4%
    4/1/2000 -318,000,000.0 -18.9% $51.07 39.6%
    4/1/1999 -392,000,000.0 -5.7% $36.57 142.2%
    4/1/1998 -415,800,000.0 6.3% $15.1 47.2%
    4/1/1997 -391,300,000.0 75.1% $10.26 -16.0%
    4/1/1996 -223,500,000.0 55.3% $12.21 22.7%
    4/1/1995 -143,900,000.0 53.6% $9.96 70.0%
    4/1/1994 -93,700,000.0 -55.4% $5.86 27.9%
    4/1/1993 -209,900,000.0 -4.5% $4.58 -31.6%
    4/1/1992 -219,800,000.0 147.5% $6.7 11.3%
    4/1/1991 -88,800,000.0 61.2% $6.02 317.4%
    4/1/1990 -55,100,000.0 67.5% $1.44 98.3%
    4/1/1989 -32,900,000.0 - $0.73 -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

  • Capital expenditures (capex) are funds used by a company to acquire, upgrade, and maintain physical assets such as property, plants, buildings, technology, or equipment. CapEx is often used to undertake new projects or investments by a company. Making capital expenditures on fixed assets can include repairing a roof, purchasing a piece of equipment, or building a new factory. This type of financial outlay is also made by companies to maintain or increase the scope of their operations.

    For more detailed definitions, please see Investopedia.